Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2005 1
2006 1
2010 2
2011 2
2012 1
2014 1
2015 2
2016 5
2017 5
2018 1
2020 2
2021 3
2022 3
2023 7
2024 13
2025 54

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 40608828

101 results

Results by year

Filters applied: . Clear all
Page 1
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Hemmingsen B, et al. Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article.
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.
Ciudin A, Johansson E, Zimner-Rapuch S, Dimitriadis GK, Bertrand M, Curteis T, Clark LJ, Fan L, Sapin H, Bergmann JF. Ciudin A, et al. Diabetes Obes Metab. 2025 Sep;27(9):4709-4719. doi: 10.1111/dom.16508. Epub 2025 Jun 19. Diabetes Obes Metab. 2025. PMID: 40537987 Free PMC article. Clinical Trial.
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.
Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN; STEP-HFpEF Trials Committees and Investigators. Davies MJ, et al. Lancet Diabetes Endocrinol. 2025 Mar;13(3):196-209. doi: 10.1016/S2213-8587(24)00304-8. Epub 2025 Jan 20. Lancet Diabetes Endocrinol. 2025. PMID: 39848268 Clinical Trial.
101 results